On Jan. 06, Yang Michael J. divested U.S. $59,741 in shares of ACADIA Pharmaceuticals Inc.. The EVP, CCO sold 1,120 shares at a price per share of $53.34. The transaction decreased this specific insider’s holdings to 8,059 shares worth around $0.43 million at present.
Another 678 shares were sold by Kim Austin D., for more than $36,165 in total proceeds. The EVP, GC dumped the shares at a price of $53.34 and the insider now owns almost 5,518 shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
That same day, Ridloff Elena sold 1,016 shares. The EVP, CFO divested U.S. $54,193 in shares of ACADIA Pharmaceuticals Inc. at a price per share of $53.34. The transaction decreased this specific insider’s holdings to 3,901 shares worth around $207260.13 at present.
Stankovic Srdjan R. sold 93,077 shares. The Pres divested U.S. $5,130,031 in shares of ACADIA Pharmaceuticals Inc. at a price per share of $55.12. The transaction decreased this specific insider’s holdings to 20,247 shares worth around $1075723.11 at present.
Davis Stephen sold 3,484 shares. The CEO divested U.S. $185,837 in shares of ACADIA Pharmaceuticals Inc. at a price per share of $53.34. The transaction decreased this specific insider’s holdings to 24,482 shares worth around $1300728.66 at present.
Mizuho launched its ACADIA Pharmaceuticals Inc. [ACAD] rating to the equivalent of a Buy and assigned the price target of $69, in a research note dated December 16, 2020. That figure represents around a 23.0% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with Mizuho’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in mid December. Meanwhile, Raymond James had raised its rating on ACAD to “Strong buy” from the earlier “an Outperform”, in a research note produced for clients November 16, 2020. In addition, there was a new coverage from Raymond James on August 25, 2020. The research firm rated ACAD “an Outperform”.
Is ACADIA Pharmaceuticals Inc. [NASDAQ:ACAD] a Good Buy Right Now?
It should be noted that ACAD technical indicators for short, intermediate as well as long term progress have placed an overall average of 64% as Buy. The average signal changed from 72% Buy in the last week and compares with 80% Buy in the past month. Data from ACADIA Pharmaceuticals Inc.’s Trend Spotter indicated that the signals were Falling. The stock current average is 0.91 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 1.01 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 50% Buy and the 100-day average volume stands at 1.05 million shares.
ACAD Price Performance
On Wall Street, ACADIA Pharmaceuticals Inc. [NASDAQ:ACAD] finished Friday’s session down -3.38% at $53.13. The stock went up to $55.85 at the same session while its lowest single day price was $52.80. In the last five days, it saw a fall of about -0.62%, ACADIA Pharmaceuticals Inc. shares dropped by almost -0.62% since the beginning of the year. However, the share price has dropped to as low as -9.52% below its one year high. On 01/08/21, the company shares recorded $55.85, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/06/21, the same year at $51.04. The company’s shares have inclined by 16.58% in the past year. The 50-day SMA achieved is $52.65 while the 200-day SMA is $46.97. Volume gained to 1.06 million from 0.92 million in the previous session.
ACAD Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 52.00 level, and in case of violation of this particular level, it will cause more drop to 50.88 level. On the upper level, 56.98 is still the key resistance. The stock may increase to the subsequent resistance at 55.05. The Relative Strength Index (RSI) pinned on the 14-day chart is 48.88, implying a neutral technical stance while the MACD stands at -0.21, meaning price will decrease in the next trading period. Percent R indicator moved to 66.83%, implying low price movement. Stochastic %K at 46.51% suggest holding the stock.
What is the short interest in ACADIA Pharmaceuticals Inc.?
Short interest in the ACADIA Pharmaceuticals Inc. stock has surged, increasing by 0.97 million shares to total 7.03 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 8.0 million, data from Yahoo Finance shows. The decrease of -13.8% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 7.71% of the overall float for the stock.
ACADIA Pharmaceuticals Inc.’s Biggest Shareholders: Who Owns ACADIA Pharmaceuticals Inc. [ACAD]?
Filings by Baker Bros. Advisors LP showed that the firm now holds a total of 41,904,586 shares or roughly 26.36% of the outstanding ACAD shares. This means their shares have reduced by 0 from the 41,904,586 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Fidelity Management & Research Co updated stake is worth $1,116,866,848. Details in the latest 13F filings reveal that T. Rowe Price Associates, Inc. disposed off their -7.09% stake valued at $597,034,239 while The Vanguard Group, Inc. cut theirs at $576,996,203. During the last quarter, T. Rowe Price Associates, Inc. liquidated -804,648 of its shares in ACADIA Pharmaceuticals Inc. while The Vanguard Group, Inc. sold -288,892 shares. The BlackRock Fund Advisors’s holdings currently number 6,200,636 shares at $329439790.68. According to the firm’s last 13F report, Janus Capital Management LLC shares in the company at filing stood at 5,706,104 shares, roughly $323,307,853.
ACAD Earnings Forecast For The Current Quarter
ACADIA Pharmaceuticals Inc. [ACAD] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $123.2M and an earnings per share of -$0.47 for Dec 2020. Looking further ahead, the company is expected to report revenue of $117.4M at an EPS of -$0.52 for Mar 2021. The estimates represent upside of 54.20% and 45.10% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
ACAD Earnings Estimates For The Current Year
For the financial year, ACADIA Pharmaceuticals Inc. [NASDAQ:ACAD] is expected to bring in revenue of $444.01M. The returns are nearly $104.93 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -1.84, lower than that of FY19 by -$0.24. Estimates put this year’s earnings growth at -15.00%, 45.10% for the next, and at an annual 25.00% over the next 5-year period. As for sales, forecasts are for an increase of 30.90% in the current fiscal year and a further 54.20% over the following year.
What are analyst thoughts on ACADIA Pharmaceuticals Inc.?
Looking forward to the ACADIA Pharmaceuticals Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for ACADIA Pharmaceuticals Inc. stock at $60.00 within the next 12 months, which represents almost 11.45 per cent growth from its previous closing price of $53.13. The highest analysts’ target for ACADIA Pharmaceuticals Inc. stock projections is $72.00 and the lowest one is $42.00. Still, 20 analysts sharing their consensus rating for ACAD stock in 2021 agree that it is a Buy.